<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03591965</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-008-HCC-001</org_study_id>
    <nct_id>NCT03591965</nct_id>
  </id_info>
  <brief_title>Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects</brief_title>
  <official_title>An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antengene Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antengene Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Asian multi-regional clinical trial (MRCT) in which ATG-008 will be administered
      orally to hepatitis B positive (HBV+) HCC subjects who have received at least one prior line
      of systemic therapy. It is designed as an open-label phase 2 trial evaluating the
      pharmacokinetics (PK), safety, tolerability and efficacy of oral ATG-008 administered daily
      until the radiologic disease progression (according to RECIST 1.1) or intolerable toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 - Day 15</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Day 1 - Day 15</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of treatment emergent adverse events (TEAEs) &amp; SAE assessed by CTCAE v4.03</measure>
    <time_frame>365 DAYS</time_frame>
    <description>The treatment emergent adverse events (TEAEs) &amp; SAE case No. in total subject No.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>365 DAYS</time_frame>
    <description>Percentage of subjects with PR, or CR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>365 DAYS</time_frame>
    <description>Kaplan-Meier estimate of Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP</measure>
    <time_frame>365 DAYS</time_frame>
    <description>The time from the first dose date until disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>365 DAYS</time_frame>
    <description>The time from the first dose date until disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>365 DAYS</time_frame>
    <description>The percentage of subjects with CR, or PR or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>365 DAYS</time_frame>
    <description>The time from the criteria are first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR</measure>
    <time_frame>365 DAYS</time_frame>
    <description>The time from the first dose date to the first documentation of response of PR or better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6, 9 and 12 month of survival rate</measure>
    <time_frame>365 DAYS</time_frame>
    <description>Percentage of patients alive</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Potential biomarkers in plasma and tumor tissues</measure>
    <time_frame>365 DAYS</time_frame>
    <description>The changes in potential biomarkers including but not limited to TORC1/TORC2 activity in peripheral blood samples and tumor tissue following treatment with ATG-008</description>
  </other_outcome>
  <other_outcome>
    <measure>Additional metabolites of ATG-008 in plasma and urine</measure>
    <time_frame>Day 1 - Day 15</time_frame>
    <description>Additional metabolites of ATG-008 in plasma and urine, and the extent of their urinary excretion/clearance</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>ATG-008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To enroll approximately 40 hepatitis B virus (HBV) positive, unresectable HCC subjects who have previously received at least one prior line of systemic therapy. Among which, approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg, once daily (QD) and another approximately 20 subjects will receive oral ATG-008 at an initial dose of 20 mg, twice daily (BID). The pharmacokinetic (PK) samples will be collected from 10 subjects each in the two dose groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-008</intervention_name>
    <description>Approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg/QD and another 20 subjects will receive oral ATG-008 at an initial dose of 20mg/BID for 28 days each cycle.</description>
    <arm_group_label>ATG-008</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged from 18 to 70 years (inclusive) at the time when the ICF is
             signed.

          2. Confirmed diagnosis of HCC.

          3. Unresectable stage B or C HCC according to the Barcelona Clinic Liver Cancer (BCLC)
             staging.

          4. HBV positive by serum test.

          5. Received at least one prior line of systemic therapy.

          6. ECOG performance status score of 0 or 1.

          7. Satisfactory serum chemistry results

          8. Adequate bone marrow function

          9. Child-Pugh A without encephalopathy.

         10. All subjects who participated in the study had to take reliable contraceptive measures
             within the trial and 3 months of after the trial.

        Exclusion Criteria:

          1. Symptomatic central nervous system metastases.

          2. Locoregional HCC therapy, systemic chemotherapy, hormonal therapy or investigational
             therapy within 4 weeks prior to Screening.

          3. Life expectancy of less than 3 months.

          4. Prior therapy with mTOR inhibitors.

          5. Prior organ transplant.

          6. Persistent diarrhea or malabsorption.

          7. Clinically significant bleeding.

          8. Known history of human immunodeficiency virus (HIV) infection.

          9. Uncontrolled intercurrent illness.

         10. Any condition that confounds the ability to interpret data from the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Xie, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jasmine Sun, MD</last_name>
    <phone>86-21-32501060</phone>
    <email>jasmine.sun@antengene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junnan Li</last_name>
    <email>junnan.li@antengene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Hospital of Haerbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuxian Bai</last_name>
      <email>bai_yuxian@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China People PLA 81 Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shukui Qin</last_name>
      <phone>86-25-80864748</phone>
      <email>qinsk@csco.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Li</last_name>
      <email>jdyylw@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Province Oncology Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sahnzhi Gu</last_name>
      <email>105575191@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daping Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Wang</last_name>
      <email>Dongwang64@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of Chongqing medical university</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengyou Du</last_name>
      <email>duchengyou@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiehe Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Lin</last_name>
      <email>13950482366@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Nanfang Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yabing Guo</last_name>
      <email>gyabing@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijia Fang</last_name>
      <email>weijiafang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Province Oncology Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieer Ying</last_name>
      <email>jieerying@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Anhui medical university</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kangsheng Gu</last_name>
      <email>13805692145@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of Anhui medical university</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengdong Chen</last_name>
      <email>chenzhendong@csco.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohua Hu</last_name>
      <email>gxykdhxh@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiqiang Meng</last_name>
      <email>mengfudan2018@yeah.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenggang Ren</last_name>
      <email>ren.zhenggeng@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of the Northern War Zone of the Chinese People's Liberation Army</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengdong Zheng</last_name>
    </contact>
    <contact_backup>
      <email>mylonzzdong@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital of China PLA fourth medical university</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helong Zhang</last_name>
      <email>zhanghelong@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nan-ji Ha</last_name>
      <phone>82 51 240 2588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National Univ. Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung hee Bark</last_name>
      <phone>82 51 240 7079</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National Univ. Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye-ran Kim</last_name>
      <phone>82 53 200 6357</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwang-Hyub Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye-min Lee</last_name>
      <phone>82 2 3010 6280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min-kyoung Kim</last_name>
      <phone>82 2 2072 7450</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung-hee Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Fang Chiu</last_name>
      <phone>04-22053366</phone>
      <phone_ext>5022</phone_ext>
      <email>d5686@mail.cmuh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei-Jer Chen</last_name>
      <phone>02-2312-3456</phone>
      <phone_ext>67072</phone_ext>
      <email>peijerchen@ntu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Yu Kao</last_name>
      <phone>02-2737 2181</phone>
      <phone_ext>3577</phone_ext>
      <email>121021@tmuh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yee Chao</last_name>
      <phone>02-28757618</phone>
      <email>ychao@vghtpe.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital-Linkuo</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsai-Sheng Yang</last_name>
      <phone>03-328-1200</phone>
      <phone_ext>8825</phone_ext>
      <email>a481124@adm.cgmh.org.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

